Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Chronic Leukemias Drugs > Drugs > Flashcards

Drugs Flashcards

1
Q

Acalabrutinib (Calquence)

A

CLL
First line
Bruton Tyrosine Kinase (BTK) inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Alemtuzumab (Campath)

A

CLL
exclusively available via compassionate use program
Anti-CD52 monoclonal antibody

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Asciminib (Scemblix)

A

CML
chronic phase CML pts w/ T315I mutation or chronic phase CML with resistance or intolerance to at least 2 prior kinase inhibitors
BCR/ABL and STAMP TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Bendamustine (Bendeka; Treanda; Belrapzo)

A

CLL
chemo used in combination with rituximab or obinutuzumab
alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Bosutinib (Bosulif)

A

CML
first line and chronic phase CML
BCR/ABL TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Chlorambucil (Leukeran)

A

CLL
alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cyclophophamide

A

CLL
alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Dasatinib (Sprycel)

A

CML
first line and chronic phase
BCR/ABL TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Duvelisib (Copiktra)

A

CLL
relapsed/refractory CLL after 2 prior therapies
PI3K inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Fludarabine (Fludara)

A

1st line+ CLL in combination with cyclophosphamide and/or rituximab
Antimetabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

hydroxyurea (Hydrea)

A

Typically used for cytoreduction prior to definitive treatment initiation
Antimetabolite

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

ibrutinib (Imbruvica)

A

1st line+ CLL
Bruton Tyrosine Kinase (BTK) inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

idelalisib (Zydelig)

A

Relapsed CLL in combination with rituximab
PI3K inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

imatinib (Gleevec)

A

1st line+ Chronic phase CML
BCR/ABL TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

nilotinib (Tasigna)

A

1st line+ Chronic phase CML
BCR/ABL TKI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

obinutuzumab (Gazyva)

A

CD20 mAb preferentially administered in combination therapies
Anti-CD20 monoclonal antibody

17
Q

ofatumumab (Arzerra)

A

Exclusively available via Patient Access Novartis Oncology (PANO) program
Anti-CD20 monoclonal antibody

18
Q
A

omacetaxine mepesuccinate (Synribo)
Chronic phase, or patients who progress to accelerated phase CML, who are resistant or intolerant to 2 or more TKIs. Note: not indicated for patients who present with accelerated phase CML
Cephalotaxine; Protein Synthesis inhibitor

19
Q

ponatinib (Iclusig)

A

Chronic phase CML patients with T315I mutation or chronic phase CML with resistance or intolerance to at least two prior kinase inhibitors
BCR/ABL TKI

20
Q

rituximab (Rituxan and biosimilars)

A

CD20 mAb preferentially administered in combination therapies

21
Q

venetoclax (Venclexta)

A

1st line+ CLL
BCL-2 inhibitor

22
Q

zanubrutinib (Brukinsa)

A

Current NCCN guidelines recommend zanubrutinib as a category 1, preferred regimen for CLL with and without del(17p)/TP53 mutation for 2nd line and subsequent therapy
Bruton Tyrosine Kinase (BTK) inhibitor

Chronic Leukemias Drugs (1 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions